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Recent reports of adverse psychiatric events from seemingly different types of weight loss therapies highlight
a previously underestimated overlap between CNS circuits that control energy balance and those that regu-
late mood. In this Perspective, we discuss a few potential brain sites where the homeostatic and the hedonic
pathwaysmay intersect and suggest that a better understanding of both pathways is necessary for the devel-
opment of more effective and safer antiobesity therapies.Introduction
The rates of obesity are rising worldwide and have become
a major public health problem (Must et al., 1999). Obesity is
usually the result of excessive caloric intake coupled with a
lack of physical activity. While lifestyle changes such as dieting
and physical exercises may provide nonpharmacological and
nonsurgical means toward body weight reduction, their long-
term success is rather limited. As a result, development of effec-
tive medical interventions remains a goal for sustained body
weight management.
The past few decades have witnessed several attempts to
develop pharmaceutical weight loss agents. A majority of these
agents targeted appetite, and several were effective in reducing
excessive food intake in overweight or obese patients. Unfortu-
nately, many drugs and candidate drugs were either withdrawn
from the market or rejected after preclinical studies. Indeed, it
was not until last year that Qsymia (a combination of phenter-
mine and topiramate) and Belviq (Lorcaserin, a selective agonist
for serotonin 2C receptor) became the first two FDA-approved
anorectics for antiobesity treatment after a span of nearly 15
years. Prominent among previously failed attempts were seroto-
nergic agents such as d-fenfluramine, a key component of the
once popular diet pill Fen-Phen (Rowland and Carlton, 1986).
However, this category of drugs was subsequently removed
from the U.S. market after reports of adverse cardiopulmonary
events due to their actions on the cardiac valves (Connolly
et al., 1997). To circumvent this problem, newer classes of
appetite suppressants such as Rimonabant and Taranabant
were developed with fewer cardiovascular side effects. Both
compounds block the endocannabinoid system and promote
sustained weight loss as well as favorable changes in cardiome-
tabolic risk factors (Despre´s et al., 2005). However, new issues
emerged with the use of this class of drugs. In particular, an
unexpected higher incidence of psychiatric problems such as
depression and anxiety were noted in overweight or obese pa-
tients taking Rimonabant (Teff and Kim, 2011). Coincidentally,
several recent studies found an overrepresentation of compul-
sive behaviors and even suicidality in patients following bariatric902 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.surgery (Peterha¨nsel et al., 2013), which is currently the most
effective and widely popular antiobesity therapy.
The potential adverse psychiatric events from seemingly
different types of weight loss therapies may not be mere coinci-
dence, but more likely point to an underappreciated area
of biology. A connection between dieting and untoward psychi-
atric responses has been noted since 1950s (Hamburger, 1951;
Stunkard and Rush, 1974). However, the underlying causes re-
mained elusive. Fortunately, recent advances in our understand-
ing of the neural circuitry of body weight regulation are starting to
shed light on this issue. One interpretation of these reports is that
approaches that induce weight loss not only target homeostatic
pathways that control energy balance, but also influence brain
circuits that are involved in reward and emotional processing.
The unexpected psychiatric effects, together with recent find-
ings that commonly used atypical antipsychotic drugs (AAPDs)
cause a significant increase in food intake and weight gain in hu-
mans (McCloughen and Foster, 2011), reveal previously under-
estimated levels of overlap between neurocircuits that regulate
energy homeostasis and those that regulate emotional behav-
iors. That these systems are so intertwined poses a critical chal-
lenge toward the development of safe and effective antiobesity
therapies. In this Perspective, we will briefly review recent re-
ports regarding the brain pathways regulating energy balance.
We will also discuss potential intersections of these brain path-
ways and those regulating mood. We predict that a greater un-
derstanding of these pathways may help guide the development
of safe and effective antiobesity therapies. However, it is not our
goal to provide a comprehensive review of a large literature
regarding untoward neuropsychiatric effects from antiobesity
agents and surgeries. Rather, we hope that our comments will
serve as a starting point for the wide readership of Cell
Metabolism to think about these potentially important issues.
We also hope that the points we raise here will lead them to
dig deeper into the established literature and to think about
studies that could be done to address issues that impede trans-
lating the explosion of basic science into effective strategies to
combat obesity.
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Two parallel regulatory systems have been implicated in the
central control of feeding behaviors (Kenny, 2011). The homeo-
static system regulates food intake in response to changes in
peripheral energy status and thus is essential for the regulation
of hunger and satiety. The neural circuits underlying this include
anatomically defined hypothalamic and brainstem nuclei where
metabolic signals such as glucose and various dietary-derived
lipids are sensed and integrated to direct proper energy intake
and expenditure (Elmquist et al., 2005). One key structure is
the arcuate nucleus of the hypothalamus (ARH), which is made
up of two distinct neuronal cell types that serve as the first-order
neurons in the brain relaying peripheral nutrient and hormonal in-
formation. Neurons that produce pro-opiomelanocortin (POMC)
and cocaine-amphetamine-regulated transcript (CART) pep-
tides suppress food intake, whereas those that synthesize
agouti-related peptide (AgRP) and neuropeptide Y (NPY) directly
promote feeding behaviors (Aponte et al., 2011; Krashes et al.,
2011). Leptin, the circulating adiposity hormone, stimulates
POMC neurons while reciprocally hyperpolarizing orexigenic
AgRP/NPY neurons. Years of studies have also highlighted an
important role for brainstem neurons in the regulation of hunger
and satiety (Grill and Hayes, 2012; Moran et al., 2006). For
instance, it was recently shown that neurons in the nucleus
tractus solitarius (NTS) and caudal serotonergic nuclei provide
excitatory inputs to the parabrachial nucleus (PBN) and inhibit
food intake (Wu et al., 2012). Furthermore, acute activation
of NTS POMC neurons produces an anorexigenic effect (Zhan
et al., 2013).
In addition to homeostatic regulation, central control of food
intake involves other neural processes such as reward and
cognition (referred to as nonhomeostatic regulation). Food,
especially palatable food, represents a potent reward signal
that stimulates the mesolimbic dopamine (DA) pathways (Kenny,
2011). Exposure to food cues promotes the firing of DA neurons
in the ventral tegmental area (VTA), resulting in an increase in DA
release in the striatum (Norgren et al., 2006; Small et al., 2003).
Intriguingly, decreased striatal DA signaling has been associated
with reduced responsiveness to reward signals in obese patients
(Geiger et al., 2008), which may perpetuate overeating through
a counterregulatory mechanism (Johnson and Kenny, 2010;
Stice et al., 2008). In particular, DA neurotransmission in the
striatum regulates motivational aspects of feeding behaviors
and is required for food procurement and consumption. Mice
deficient in DA production die of starvation due to a lack of
motivation to feed, a defect that can be rescued by restoring
DA in the dorsal striatum (Szczypka et al., 2001). Interestingly,
a lack of motivation for palatable food or anhedonia is often
viewed as one of the hallmarks of depressive symptoms. Consis-
tently, reduced activities of mesolimbic DA system have been
implicated in the pathophysiology of major depressive disorder
(MDD), whereas euphoria is associated with amphetamine-
induced DA release in the ventral striatum (Drevets et al., 2001;
Nestler and Carlezon, 2006). Together, these findings suggest
that functional impairments of the mesolimbic DA system can
affect both emotional and metabolic processing.
In addition to the mesoaccumbens DA circuits, other limbic
regions (amygdala and hippocampus) and cortical (orbitofrontal
cortex [OFC], anterior cingulated cortex [ACC], and insula) alsoencode the hedonic value of food cues and are responsible for
the cognitive regulation of feeding behaviors (Pelchat et al.,
2004; Simmons et al., 2005). For example, the presentation
of food to fasting subjects increased metabolism in the OFC in
proportion to the subjective perception of hunger and the desire
to eat (Wang et al., 2004). Conversely, decreased activities were
found in the amygdala, hippocampus, insula, and OFC when
fasted men were asked to voluntarily inhibit their food cravings
while being exposed to food cues (Wang et al., 2009). Notably,
these brain sites are strongly implicated in mood regulation,
and their malfunction may also contribute to emotional perturba-
tions (Bachevalier et al., 2011).
Unanticipated Actions of Antiobesity Drugs
Untoward psychiatric events may arise from the fact that several
antiobesity agents target proteins that have broad expression
domains in the central nervous system. As a result, global manip-
ulation of their activities may inevitably affect their functions in
brain sites that are involved in mood regulation. Prominent ex-
amples in this regard are found in the former drugs Rimonabant
and Taranabant, antagonists of cannabinoid receptor 1 (CB1).
The appetite-stimulating effects of cannabis plants have been
documented for centuries. However, the underlying mechanism
remained unclear until the discovery of the first cannabinoid
receptor (CB1), a G protein-coupled receptor that binds
delta(9)-tetrahydrocannabinol (D9-THC), the principal psycho-
tropic ingredient of marijuana (Matsuda et al., 1990). Two major
cannabinoid receptors (CB1 and CB2) exist in the mammalian
endocannabinoid system to mediate the neuromodulatory ac-
tions of endogenous endocannabinoids. While the expression
of CB2 receptors is largely enriched in the immune system,
CB1 receptors are abundant in the brain and responsible for
the orexigenic actions of both natural and endogenous cannabi-
noid ligands (Howlett, 2002). Elevated CB1 receptor signaling
has been implicated in obesity and its comorbid metabolic
syndromes (Matias et al., 2008; Osei-Hyiaman et al., 2005;
Ruby et al., 2011). Rimonabant (Acomplia, Sanofi-Aventis),
a selective CB1 receptor blocker, induced significant weight
loss and improved cardiometabolic risk profiles in overweight
or obese patients (Despre´s et al., 2005; Pi-Sunyer et al., 2006;
Van Gaal et al., 2005). The positive results from multiple preclin-
ical studies led to the approval of Rimonabant in 2006 as a novel
anorectic antiobesity treatment by the European Medicines
Agency (EMEA). By 2008, the drug was available in more than
50 countries. However, following its clinical introduction,
adverse neuropsychiatric incidents including anxiety, depres-
sion, and suicidality were noted in obese patients, leading to a
growing concern regarding the psychiatric safety of this drug.
Consequently, Rimonabant was removed from the global market
following its suspension by the EMEA in late 2008. Meanwhile,
the clinical development of similar compounds including Tarana-
bant (Merck) and Otenabant (Pfizer) were also abandoned
(Le Foll et al., 2009).
The antiobesity effect of this type of drug is thought to be
principally mediated by its anorexigenic function. Of note,
when given at a subthreshold dose, Rimonabant selectively
reduces the intake of palatable food, but has no effect on the
feeding of regular food, suggesting that CB1 receptor signaling
is not only involved in the regulation of satiety, but may alsoCell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 903
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haviors (Simiand et al., 1998). Within the hypothalamus, one of
the crossroads where CB1 receptors regulate both homeostatic
and nonhomeostatic feeding is the lateral hypothalamus (LH),
where activation of CB1 receptors not only promotes food intake
but also influences reward processing through interactions with
the mesoaccumbens DA system (Jo et al., 2005; Taslimi et al.,
2011).Moreover, CB1 receptor signalingmediates the orexigenic
effect of ghrelin in the paraventricular nucleus of the hypothala-
mus (PVH). Activation of CB1 receptors diminishes the excitatory
inputs on corticotrophin-releasing hormone (CRH) neurons (Kola
et al., 2008) and inhibits the release of CRH (Di et al., 2003).
Conversely, genetic ablation of CB1 receptor in rodents leads
to increased levels of CRH (Cota et al., 2003). In addition to its
role as an anorexigenic peptide, CRH is a major regulator of
the hypothalamic-pituitary-adrenal (HPA) axis. Increased levels
of CRH and HPA activities have been implicated in the patho-
physiologies of affective disorders including depression and
suicide (Bonfiglio et al., 2011). Therefore, the actions of CB1
antagonists on CRH neurons may potentially affect emotional
behaviors by altering the levels of HPA activities and stress
hormones (Ashton and Moore, 2011; Cota et al., 2007).
CB1 receptor signaling may also regulate emotional behaviors
in extrahypothalamic sites, independent of its role in the regula-
tion of food intake. CB1 receptors are highly enriched in the pre-
frontal cortex, amygdala, and hippocampus, brain regions that
are critical for emotional processing (Herkenham et al., 1990).
Stimulation of CB1 receptors in these sitesmay serve as the neu-
ral basis for the reported feelings of relaxation, reduced anxiety,
and increased sociability after cannabis use (Murray et al., 2007).
Conversely, pharmacological blockade of CB1 receptors leads
to increased anxiety-like behaviors and impaired stress-coping
capabilities in rodents (Navarro et al., 1997; Steiner et al.,
2008). It has therefore been hypothesized that a persistent
endocannabinoid tone has to be maintained in certain cortical
and limbic areas for normal emotional responses. In this vein,
global antagonism of CB1 receptors signaling may negatively
impact emotional processing and thus contribute to the patho-
physiology of affective disorders.
Unexpected Outcome of Weight Loss Surgery
A growing body of literature suggests that actions of some
peripheral metabolic signals do not exclusively regulate energy
homeostasis, but may also be directly involved in mood regula-
tion (Hryhorczuk et al., 2013). This hypothesis is further supported
by the expression of the receptors for the circulating hormones,
such as leptin, insulin, and ghrelin in extrahypothalamic sites
that have been implicated in the control of mood (Plum et al.,
2005; Scott et al., 2009; Zigman et al., 2006). These findings
therefore raise the possibility that the increased risk of adverse
psychiatric events may result from changes in the levels of circu-
lating hormones following antiobesity therapies. For example,
bariatric surgery is currently the most effective treatment for
obesity and its comorbid metabolic conditions. The surgery can
help obese patients achieve not only significant long-termweight
loss (40%–70%), but substantial improvement in hyperlipidemia
andhypertension, complete remission of diabetes, andultimately
a reduction in mortality (Mingrone et al., 2012; Schauer et al.,
2012). Hundreds of thousands of Americans receive bariatric sur-904 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.gery each year, and the number will continue to rise in the future.
However, relatively few studies have been conducted to evaluate
the long-term safety of this surgery, especially as it relates
to behavioral and psychiatric outcomes. Several studies have
suggested that following surgery and weight loss, there is an
increase in the incidence of certain maladaptive behaviors. In
particular, it has been noted that some patients developed post-
operative compulsive disorders such as alcoholism, gambling,
and compulsive shopping (Acosta et al., 2008; Wendling and
Wudyka, 2011). Most alarmingly, several groups reported an
increased risk of suicide among postoperative bariatric patients
compared with either the general population or with obese indi-
viduals who did not have the surgery (Adams et al., 2007; Peter-
ha¨nsel et al., 2013; Pories et al., 1995; Tindle et al., 2010). Among
these studies, Tindle et al. followed 16,683 bariatric surgery pro-
cedures performed on Pennsylvania residents over a ten year
period. The postsurgical suicide rate was 13.7/10,000 for men
and 5.2/10,000 for women, compared with 2.4/10,000 for age-
matched men and 0.7/10,000 for age-matched women in the
U.S. general population (Tindle et al., 2010).
Other than pre- and postoperative psychological distress, the
molecular mechanisms underlying the alterations in behavior
and suicide rates remain unknown. A sudden decrease in serum
cholesterol has been previously linked to suicide (Modai et al.,
1994). Moreover, changes in the levels of peripheral-derived
neuropeptides including leptin, glucagon-like peptide-1 (GLP-
1), peptide YY (PYY), and ghrelin have all been described
following the surgery (Ionut et al., 2013). Ghrelin, a 28 amino
acid peptide, is synthesized and secreted primarily by the
epithelial cells of the fundus (Kojima et al., 1999). Depending
on the type of the surgery, the fundus can be either isolated or
removed during the procedure, leading to a significant reduction
in serum ghrelin levels (Fru¨hbeck et al., 2004). In addition to its
role as an orexigenic peptide, a growing body of literature
indicates that ghrelin, acting through its receptors in the brain,
regulates emotional behaviors (Chuang and Zigman, 2010). For
example, plasma ghrelin level rises upon various types of stress
and may serve as a neuroprotective mechanism against stress-
induced anxiety and depression (Lutter et al., 2008). Consistent
with these findings, ghrelin produces an antidepressant-like
effect in rodents, which may be associated with adult neurogen-
esis in the hippocampus (Chuang and Zigman, 2010). Therefore,
lower serum ghrelin levels in postoperative bariatric patients
may lead to increased vulnerability and susceptibility to depres-
sion and suicide ideation. Further studies are clearly needed
to directly address this hypothesis. In addition to ghrelin, leptin
receptors are highly enriched in the hippocampus, amygdala,
and VTA (Scott et al., 2009). Leptin administration reduces the
firing rates of dopaminergic neurons within the VTA, suggesting
that leptin actions on DA neurons may directly regulate mesolim-
bic DA activity and DA-modulated behaviors (Fulton et al., 2006;
Hommel et al., 2006). Reduced levels of striatal dopamine D2
receptors have been found in drug-addicted subjects (Volkow
et al., 2007). Interestingly, Dunn et al. found a similar reduction
of D2 receptor availability in postoperative bariatric patients
accompanied by a significant decrease of plasma levels of insu-
lin and leptin (Dunn et al., 2010). It remains to be determined
whether changes in peripheral-derived hormones such as leptin
have a direct impact on mesoaccumbens DA signaling and if
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to the reports of depression, lower levels of plasma leptin have
been observed in depression patients and in rodent models of
depression (Lu et al., 2006). Conversely, systemic leptin admin-
istration produces an antidepressant-like effect and dose-
dependently improves mice performance in both forced swim
and tail suspension tests (Kraus et al., 2001; Lu, 2007). However,
it is unclear whether a drop in postoperative leptin levels ulti-
mately contributes to the altered emotional processing and the
pathophysiologies of depression and suicide.
Finally, the increased risks for adverse neuropsychiatric
events could be the result of altered gut-brain signaling following
bariatric surgery (Berthoud et al., 2011). It is well known that
the metabolic actions of several gut-derived neuropeptides
and transmitters including cholecystokinin (CCK), PYY, GLP-1,
ghrelin, and serotonin are mediated, in part, through the vagal
afferents (Moran, 2009). The vagus nerve is the tenth cranial
nerve that arises from the brain stem and innervates key visceral
organs including the entire gastrointestinal tract. Various visceral
signals collected by the vagal sensory neurons are initially inte-
grated in the NTS in the brain stem and ultimately reach the
cerebral cortex via parabrachial-thalamic and other ascending
pathways (Saper, 2002). It has long been proposed that visceral
inputs are integrated with emotional experience and can poten-
tially affect psychiatric functioning (Stellar, 1954). Moreover,
vagal nerve stimulation has been clinically used to combat treat-
ment-resistant depression. However, many of the mechanisms
underlying the beneficial effects of vagal stimulators remain
poorly understood. Recently, Tellez et al. reported that lipid
sensing by vagal afferents can influence the striatal release of
DA and DA-modulated feeding behaviors (Tellez et al., 2013).
Both ventral and dorsal branches of the gastric vagus nerves
are severed during Roux-en-Y gastric bypass (RYGB) surgery.
It is therefore important to investigate whether the surgery-asso-
ciated gastric vagotomy may contribute to these potential mal-
adaptive behavioral responses.
Body Weight Effects of Psychiatric Agents
Excess weight and obesity are associated with mood disorders
(Petry et al., 2008). A large number of epidemiologic and clinical
studies indicate obese patients are more susceptible to psychi-
atric illnesses, raising the possibility thatmetabolic abnormalities
may precipitate mental illness (Faith et al., 2011). On the other
hand, a broad range of psychotropic agents, including various
antidepressants, mood stabilizers, and antipsychotics, can
cause significant weight gain. Among different psychiatric
agents, abnormal weight gain is most prominent within individ-
uals taking AAPDs. AAPDs are second-generation antipsychotic
agents and, despite their metabolic side effects, are frequently
prescribed to treat several psychiatric conditions including
depression, bipolar disorder, and schizophrenia. Standard
doses of AAPDs can cause rapid weight gain of more than
4 kg over a 10 week period (Allison and Casey, 2001). In addition,
other metabolic impairments including hyperglycemia, hyper-
tension, hypertriglyceridemia, and low HDL cholesterol are also
prevalent among patients taking AAPDs (Bergman and Ader,
2005). The risks for developing metabolic syndromes vary be-
tween individual AAPDs, among which clozapine and olanzapine
have the greatest side effects (Teff and Kim, 2011). Moreover,children and young adults seem to be the most susceptible
to developing metabolic abnormalities and tend to gain more
weight during AAPD treatment (Almandil and Wong, 2011). The
mechanism underlying AAPD-induced weight gain remains
unknown. However, an increase in food cravings has been
consistently reported following olanzapine and clozapine
administration (Kluge et al., 2007), suggesting that AAPDs
cause weight gain through actions on neurocircuits that regulate
appetite.
AAPDs exert their psychotropic actions by antagonizing
receptors for biogenic amines, including dopaminergic, adren-
ergic, muscarinic, histaminergic, and serotonergic receptors
(Bymaster et al., 1999), many of which have been directly or
indirectly implicated in feeding regulation. Previous work has
focused on the central histamine system and showed that
AAPDs’ binding affinity for the histamine H1 receptor (H1R)
was significantly correlated with body weight gain (Kroeze
et al., 2003). Furthermore, pharmacological and genetic ablation
of H1Rs results in hyperphagia and obesity (Masaki et al., 2004).
In addition to the H1R signaling, AAPD-induced weight gain is
associated with polymorphisms in the serotonin 2C receptor
(Htr2c) gene (Reynolds et al., 2002; Templeman et al., 2005).
Global deletion of Htr2c causes hyperphagia and obesity in
mice (Nonogaki et al., 1998; Tecott et al., 1995). Our lab has
recently identified the POMC neuron in the ARH as one of the
physiologically important sites where Htr2c regulates food
intake. Furthermore, selective re-expression of physiological
levels of Htr2c only in POMC neurons is sufficient to normalize
hyperphagia and obesity in Htr2c null mice (Xu et al., 2008).
Conversely, Htr2c expression in POMC neurons is required to
effectively regulate energy balance and glucose homeostasis
(Berglund et al., 2013). To this end, it will be interesting to inves-
tigate whether AAPD-induced hyperphagia and weight gain
involves antagonism of Htr2c in POMC neurons.
Perspectives
The neural control of energy balance and emotional behaviors
are both complex physiological processes that involve coordi-
nated actions of multiple brain structures and neurotransmitter
systems. Therefore, it is not surprising that common pathways
have ‘‘dual’’ functions and contribute to both metabolic and
emotional regulation. A prime example of ‘‘shared pathways’’
is the mesolimbic DA system that not only encodes for the
hedonic value of palatable food, but is heavily implicated in the
pathophysiology of emotional disorders such as schizophrenia
and depression. Consistently, impairments in mesolimbic DA
signaling can cause both obesity and anhedonia, a major clinical
symptom of depression. Within the hypothalamus, however,
accumulating evidence suggests that several neuronal popula-
tions influence emotional processing independently of their
roles in the homeostatic regulation of energy balance. For
example, the CRH neurons in the PVH play a crucial role in
regulating circulating levels of glucocorticoid hormones, which
are elevated in response to stress and in patients with major
depression (Manji et al., 2001). Additionally, LH orexin neurons
modulate motivation by direct innervation and stimulation
of DA neurons in the VTA (Narita et al., 2006). Within the arcuate
nucleus, b-endorphin, another splicing product of POMC, has
been implicated in major depression (Hegadoren et al., 2009).Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc. 905
Cell Metabolism
PerspectiveMoreover, a recent study highlighted a role for AgRP neurons
in the regulation of midbrain DA neuron activities and DA-asso-
ciated reward behaviors (Dietrich et al., 2012).
Without a doubt, these recent findings strongly suggest that
neural pathways that regulate metabolism and those that regu-
late emotional behaviors are intimately intertwined and are not
easy to target in isolation. In fact, many think that untangling
this intimate relationship is not feasible, and drugs that target
the CNS ‘‘feeding circuits’’ are often nonstarters as potential
candidates. Whether this is the case or not remains to be seen.
Nonetheless, these findings provide fuel to a widely held notion
that antiobesity therapies that directly or indirectly affect the
central nervous system (CNS) are likely to carry inherent risks
for negative psychiatric events. Optimizing the benefit/risk pro-
file remains a key challenge for the development of safe and
effective antiobesity therapies. In this regard, the adverse neuro-
psychiatric events associated with recent antiobesity therapies
provide valuable lessons for new drug development. We argue
that developing protocols that allow for the early preclinical
detection of adverse psychological effects is imperative for
the development of future CNS-targeted antiobesity agents.
On the other hand, a revisit of the peripheral functions of several
existing pharmacological targets may be necessary so that it is
possible to develop periphery-restricted antiobesity agents
without incurring CNS-related side effects. For example, studies
suggest that many of the metabolic benefits of CB1 receptor
antagonists (potentially the anorexic effects) can be mediated
through their actions on peripheral CB1 receptors (Go´mez
et al., 2002). These findings raise the possibility of developing
novel peripherally restricted CB1 receptor antagonists to circum-
vent the neuropsychiatric complications that are certainly medi-
ated by the CNS.
Regardless of the aforementioned issues, at the end of the
day we posit that a better understanding of the neurocircuits
that control energy balances and those regulating emotional
behaviors, as well as how these pathways interact, remains
essential for identifying novel and more refined targets for
pharmacological intervention. Notably, several new approaches
that allow for targeted drug delivery and selective nerve stimu-
lation are being developed so that only anatomically defined
feeding circuits and pathways are affected by these therapies.
For example, Finan et al. recently described a new combinatorial
approach that used a GLP-1-estrogen conjugate to selectively
activate estrogen receptors only in GLP-1-targeted tissues
(Finan et al., 2012). Using this approach, the authors were able
to improve obesity, hyperglycemia, and dyslipidemia in diet-
induced obese mice while minimizing the side effects that are
commonly associated with traditional estrogen therapies. It
remains to be seen whether similar approaches can be utilized
to direct other pharmacological agents to specific populations
of CNS neurons. Furthermore, several groups have demon-
strated the feasibility of inhibiting food intake in rodents by
selectively stimulating or inhibiting distinct hypothalamic and
brainstem circuits via either optogenetic or pharmacogenetic
means (Aponte et al., 2011; Krashes et al., 2011; Wu et al.,
2012; Zhan et al., 2013). As well, hypothalamic deep brain
stimulation (DBS) has been tried in both primates and humans
and has been shown to be effective in reducing food intake
and body weight (Torres et al., 2012; Whiting et al., 2013). It is906 Cell Metabolism 19, June 3, 2014 ª2014 Elsevier Inc.therefore expected that with an improved understanding of
central pathways regulating food intake and mood, these new
approaches will significantly enhance the specificity of current
treatments and facilitate the development of future antiobesity
therapies.
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